Home
IMPACT PH Lecture Series
Education
Product Spotlight
PAH.tv Network
Slidesets and Resources
You are here :
PAH.tv Network
Login
|
Register
Please select a video from the list below.
Are Direct Oral Anticoagulants Appropriate for PAH?
Recent expert clinical guidelines support use of warfarin for PAH patients in FC III-IV. In this presentation, Dr. Ioana Preston reviews these guidelines and whether emerging direct oral anticoagulants may have a role in anticoagulation of these patients.
Slideset - Are Direct Oral Anticoagulants Appropriate for PAH?
Recent Video
|
Most Viewed
Specialties :
<All Specialties>
Allied Health
Clinical Insights
Clinical Trials
Lecturer Bios
News
PAH
Search :
Hemodynamics Markers of PH and Outcomes in Heart Failure With HFpEF
Views - 35
Clinical Worsening in Higher Risk Patients
Views - 67
Approach to Treatment in Inoperable CTEPH
Views - 116
Transitioning Patients Between PH Therapies
Views - 271
Plasma BNP Predicts 5-Year Overall Survival in PAH
Views - 289
Are Direct Oral Anticoagulants Appropriate for PAH?
Views - 357
Options When Prostacyclin Side Effects are Unmanageable
Views - 366
SIOVAC: Sildenafil for PH after Mitral Valve Surgery
Views - 1390
Macitentan in PH Due to LV Dysfunction: MELODY-1
Views - 426
Is Up-Front Triple Combination Therapy in PAH "A Thing"?
Views - 340
New Therapies for CTEPH
Views - 290
New Therapies for Group 1 PAH
Views - 371
How to Screen for PAH in Scleroderma-Spectrum Disorders
Views - 424
PAH-Related Morbidity Is Prognostic for Mortality
Views - 699
Pulmonary Hypertension Association Update
Views - 152
Getting Aggressive in PAH: Setting Goals and Escalating Care
Views - 533
Strategies for Transitioning Therapy in PAH
Views - 46
Palliative Care in PAH: Best Practice or Too Little, Too Late
Views - 56
Newer Medications and How To Use Them
Views - 75
Clinical Research Year in Review
Views - 58
Advances in Imaging for Lung Vasculature
Views - 39
Bleeding and Thrombosis After PTE
Views - 34
Serum CXC-Chemokine Ligand 10 is Associated with Severity of Chronic Thromboembolic Pulmonary Hypertension
Views - 20
NEDD9 is Upregulated By Hypoxia in Human Pulmonary Artery Endothelial Cells Selectively and Modulates Platelet-Endothelial Adhesion
Views - 27
Management of Severe Right Heart Failure in PTE Patients
Views - 29
The Imposters: What (almost) Everyone Thinks is CTEPH
Views - 22
Absence of the Factor V Leiden Mutation and Genetic Risk For CTEPH
Views - 39
Pulmonary Embolism, CTED and CTEPH: Connecting the Dots
Views - 18
Evaluation of CTEPH: VQ Scans and Planar Angiography
Views - 35
Patients with CTEPH Should Be Started on PAH Therapy Prior to PTE
Views - 28
An Overview of PH Directed Medical Therapy in CTEPH
Views - 44
CTED and the Value of Exercise Testing
Views - 16
Future Directions in CTEPH
Views - 26
Balloon Pulmonary Angioplasty for CTEPH: Patient Selection
Views - 27
CTEPH Patients Should NOT Be Started on PH Medical Therapy Before PTE
Views - 14
Mechanism of Lumen Enlargement and Pulmonary Injury In Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Views - 10
Distal Pulmonary Thromboendarterecomy: Is It Worth It?
Views - 9
Medical Decision in BPA
Views - 16
The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy
Views - 10
The Dilemma of CTEPH
Views - 88
Challenges of PAH in Heart Failure With Preserved Ejection Fraction
Views - 1388
Weighing Strategic Treatment Options in the Current Era of PAH Medicine
Views - 651
Expanding the Therapeutic Range of Current PAH Medications: What Next?
Views - 102
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
Views - 279
RESPITE Study Results
Views - 1008
Assessing Risk in PAH Patients
Views - 702
When to Add or Switch Therapy
Views - 303
RESPITE: Evidence to Support a Switch Approach?
Views - 492
Switching from PDE-5 to sGC Stimulator
Views - 252
What is Tolerance to Therapy on PDE-5 or PGI-2?
Views - 196
What are the Choices When Escalating Therapy?
Views - 901
Parameters for Treatment Success
Views - 795
When Should Patients be Evaluated for Efficacy?
Views - 307
General Goals of Therapy for Patient on Monotherapy
Views - 881
Early Combination Therapy: Applying Aggressive Goals
Views - 152
Preventing Hospitalization in PAH Through Aggressive Early Therapy
Views - 191
Future Directions in PAH Therapy and Clinical Research
Views - 532
Quality of Life Issues in the Treatment of PAH
Views - 637
What Are the Risks to Combination Therapy?
Views - 77
Neurohormone in the Pathobiology of PH: Beta-blockers
Views - 63
Palliative Care in Pulmonary Arterial Hypertension
Views - 154
Oral Prostanoids for the Mgmt of PH: The Holy Grail or Beraprost Revisited?
Views - 314
Neurohormone in the pathobiology of PH: RAAS
Views - 43
Case Presentation: Palliative Care in PAH
Views - 23
Mitral Valve Disease and the Development of Pulmonary Arteriopathy
Views - 146
Vascular and Endothelial Biomarkers in PAH
Views - 52
Case of Atrial Septal Defect Associated with PH
Views - 1647
WHO Group II PH Due to Heart Failure w/Preserved Ejection Fraction
Views - 817
Case of a 58 Year Old with Scleroderma
Views - 457
Understanding the Diagnosis and Treatment of PAH
Views - 322
20 Years of Prostanoids: Spanning the Continuum of Care in PAH
Views - 705
Group 1 and Beyond: Case Studies in PH
Views - 226
Insights from Fetal Imaging
Views - 112
Pathophysiology of PH in the ICU
Views - 108
ICU Management of PH
Views - 147
Privacy
|
Terms Of Use
|
Contact Us
|
Copyright 2018 by PAH.tv
|
About PAH.tv